Orforglipron Versus Semaglutide Researchers enrolled nearly 1,700 adults with Type 2 diabetes inadequately controlled with metformin and HbA1c levels between 53 and 91 mmol/mol
CagriSema , combining semaglutide with cagrilintide (an amylin analog), represents another approach
The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
The reported results are promising: Over 80% relative bioavailability Around 160 higher bioavailability vs oral tablets Sustained drug levels for ~1 week (once-weekly dosing potential) Additionally, the microneedle patches are stable at room temperature, eliminating the need for cold storage, unlike semaglutide injections
This triple action counteracts the signs of aging, delivering noticeable natural results after just one treatment
The USA forms the upper position
